Both Coherus BioSciences Inc. (NASDAQ:CHRS) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00 KalVista Pharmaceuticals Inc. 16.48M 18.07 14.22M -1.51 0.00 Demonstrates Coherus BioSciences Inc. and KalVista Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.
Table 2 hightlights the return on equity, net margins and return on assets of the two companies.
Risk and Volatility
Coherus BioSciences Inc. has a 3.65 beta, while its volatility is 265.00% which is more volatile than Standard and Poor’s 500. Competitively, KalVista Pharmaceuticals Inc.’s beta is 2.93 which is 193.00% more volatile than Standard and Poor’s 500.
Coherus BioSciences Inc.’s Current Ratio is 5.3 while its Quick Ratio is 5.3. On the competitive side is, KalVista Pharmaceuticals Inc. which has a 2.4 Current Ratio and a 2.4 Quick Ratio. Coherus BioSciences Inc. is better positioned to pay off short and long-term obligations compared to KalVista Pharmaceuticals Inc.
Coherus BioSciences Inc. and KalVista Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.
The average target price of Coherus BioSciences Inc. is $28, with potential upside of 120.65%.
Insider and Institutional Ownership
The shares of both Coherus BioSciences Inc. and KalVista Pharmaceuticals Inc. are owned by institutional investors at 95.7% and 78.5% respectively. Insiders held 0.1% of Coherus BioSciences Inc. shares. Insiders Competitively, held 0.8% of KalVista Pharmaceuticals Inc. shares.
Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Coherus BioSciences Inc. -10.04% -20.27% -44.41% -37.81% 17.75% 13.07% KalVista Pharmaceuticals Inc. -1.95% 24.16% 39.42% 187.68% 144.96% 141.95% For the past year Coherus BioSciences Inc.’s stock price has smaller growth than KalVista Pharmaceuticals Inc.
On 7 of the 10 factors KalVista Pharmaceuticals Inc. beats Coherus BioSciences Inc.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companyÂ’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.
Click here to view original web page at Coherus BioSciences Inc. (CHRS) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) Comparing side by side